EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real-World Sotatercept Eligibility: Analysis from the FOCUS-PAH Registry

Giulio Savonitto, Giovanni Santi, Matteo Pagnesi, Pier Paolo Bocchino, Piero Gentile, Mauro Acquaro, Mauro Driussi, Luciana D'Angelo, Francesca Macera, Luke S. Howard, Matteo Toma, Gaia Miceli, Davide Barbisan, Valentino Collini, Carlo Maria Lombardi, Carolin Bauleo, Matteo Rugolotto, Elena Bertarelli, Gianluca Pagnoni, Emanuele Bobbio, Sven-Erik Bartfay, Johanna Wermström, Laura Scelsi, Alberto Giannoni, Suela Vani, Massimo Imazio, Edoardo Airo, Francesca Coppi, Claudia Raineri, Marco Metra, Andrea Garascia, Clara Hjalmarsson, Gianfranco Sinagra, Francesco Lo Giudice, Pietro Ameri, Davide Stolfo

Respiration · 2026-06-12 · 1-11

DOI: 10.1159/000552663 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Pulmonary arterial hypertension (PAH) remains burdened by suboptimal outcomes despite contemporary therapy. Sotatercept showed clinical benefit in STELLAR and ZENITH, yet trial criteria may limit real-world implementation. We quantified real-world eligibility at baseline and during follow-up and identified baseline predictors of non-eligibility. Methods: We retrospectively analyzed 657 patients with incident PAH (2001–2024), excluding 116 with incomplete follow-up data. Inclusion criteria mirroring STELLAR were WHO functional class II/III, PVR ≥5 WU, and stable background therapy. Exclusion criteria included severe comorbidities or recent cardiovascular events. Multivariable models identified predictors of non-eligibility. Extended eligibility per ZENITH criteria was also assessed. Results: Among 541 analyzed patients, 104 (19%) were ineligible at baseline, mainly due to non-permitted PAH subtypes (71%) or vasoreactivity (29%). During a median 45-month follow-up, cumulative follow-up eligibility (i.e., patients who met criteria at least once after baseline) was 50%, with most exclusions due to PVR

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →